Computational/Experimental Biologist in Single-Cell CRISPR
We are seeking talented scientists who want to innovate at Novo Nordisk Research Centre Oxford and participate in changing the quality of life for millions of people with diabetes.
Our new Novo Nordisk Research Centre Oxford (NNRCO) Advanced Genomics team is seeking creative computational and/or experimental biologists for a challenging opportunity to study the mechanisms behind fatty liver disease, insulin resistance, and type 2 diabetes. Broadly, your responsibility will creating experimental and/or computational ex vivo and in vitro liver models used in CRISPR and drug target screens. The team is highly interdisciplinary, with wet- and dry-lab strengths, and so the role will best suit an individual intellectually stimulated by the science and in shaping the questions being asked. Individuals with backgrounds in both wet- and dry-lab science are particularly encouraged to apply. You will be expected to collaborate with cross-functional NNRCO teams in areas beyond your expertise (such as imaging), be comfortable with managing your own sequencing bioinformatic pipelines (training can be provided), and report results clearly to diabetes researchers within NNRCO, Oxford University, and Novo Nordisk Global Research.
We are recruiting from PhD to early career level, with a focus on mentoring individuals towards leading their own teams in academia or industry. This is a unique opportunity for ambitious experimental and/or computational biologists who enjoy a fast paced environment where creative intellectual independence and keenness to publish high impact work are actively encouraged.
Applicants are asked to clearly indicate, in a two page cover letter, their wet- and/or dry-lab expertise, especially in functional genomics (e.g. single-cell RNA-seq and epigenetics) and genome engineering (e.g. CRISPR and reporter systems), with examples of projects in which you have shaped the science. Please also include how you would propose to study genetic and micro-environmental variables in human liver spheroids of a few thousand cells each. Candidates invited to interview will be expected to present their proposal in detail. A third appendix/references page may be included with the cover letter. Kindly note that the intended start in the NNRCO for this position is January 1 2018.
You hold a molecular and/or data sciences PhD or equivalent. We expect you to be flexible, open to new ideas, ambitious, an out-of-the-box thinker, and result oriented. Attitude is as important as aptitude. The job requires proficiency in English and excellent communication and collaboration skills. You will be part of a team in a highly dynamic and challenging environment.
Working at Novo Nordisk
At Novo Nordisk, we use our skills, dedication and ambition to help people with diabetes. We offer the chance to be part of a truly global work place, where passion and engagement are met with opportunities for professional and personal development.
About the NNRCO Institute and the Advanced Genomics Department
Novo Nordisk is hiring scientists for our new academic-industrial hybrid research institute focused on discovery biology related to type 2 diabetes. The Novo Nordisk Research Centre Oxford (NNRCO) will interface fully with the world-leading academic type 2 diabetes research community at Oxford University. NNRCO,established in January 2017, is establishing a world-class scientific team and we hope you will join us! The institute will consist of junior and senior level faculty, post-doctoral fellows, technicians and Ph.D. students. In 2017, NNRCO will have 4 Departments: Advanced Genomics; Bioinformatics; Stem Cell Engineering; and High-Throughput Imaging, with 3 more Departments following in 2018; Proteomics, In Vitro Physiology, and In Vivo Physiology. This position is for the Advanced Genomics Department, but a successful applicant will be expected to collaborate throughout the Institution.
The NNRCO is part of Novo Nordisk’s Global Research Unit, which specialises in the discovery of biological medicines for the treatment of type 1 and 2 diabetes. We also discover and develop new innovative biopharmaceuticals for haemophilia and growth disorders. Furthermore, we conduct stem cell and beta cell regeneration research and other early-stage investigations aimed at finding a cure for diabetes, as well as exploring novel treatments for obesity and long-term, micro-vascular complications of diabetes.